NEFL and Alzheimer disease: Given the non-specificity of any “N” biomarker, including NfL and the previously described, concerns around the utility of A/T/N for determining AD specificity, clinical trial eligibility and appropriate treatment options encompassing all individuals, an opportunity emerges to step out of conventional A/T/N biomarker lanes.